NEVRO CORP
nevro.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2024 10-K, filed Mar 4, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2025.
10-K for FY2024, filed Mar 4, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Sells spinal cord stimulation systems and minimally invasive sacroiliac-joint fusion devices for physicians treating chronic pain.
10-K for FY2024, filed Mar 4, 2025We are a global medical device company focused on delivering comprehensive, life-changing solutions that continue to set the standard forโฆView โ
We developed and commercialized our HFXโข SCS platform, which includes the Senzaยฎ SCS system, an evidence-based neuromodulation system forโฆView โ
In November 2023, we acquired Vyrsaโข Technologies ("Vyrsa"), which developed and manufactured a portfolio of SI joint fusion devices, toโฆView โ
We maintain a sales organization as our main channel to communicate with our customers. Our sales representatives target physicianโฆView โ
How Did They Make Money?
Hospitals and medical facilities pay for devices delivered during implantation after the procedure is completed and authorized; customers ordering products in advance, including distributors, owe payment regardless of use. Invoices are generally due 30 to 60 days later.
10-K for FY2024, filed Mar 4, 2025For a majority of sales, where the Companyโs sales representative delivers its product at the point of implantation at hospitals or medicalโฆView โ
For the remaining sales, which are sent from the Companyโs distribution centers directly to hospitals and medical facilities, as well asโฆView โ
$408.5M
-
10-K for FY2024, filed Mar 5, 2025
$408.5M โ
Who Were Their Customers?
Sales representatives work with physicians involved in SCS treatment decisions; products are delivered to hospitals and medical facilities, and some are sold through distributors.
10-K for FY2024, filed Mar 4, 2025We maintain a sales organization as our main channel to communicate with our customers. Our sales representatives target physicianโฆView โ
For a majority of sales, where the Companyโs sales representative delivers its product at the point of implantation at hospitals or medicalโฆView โ
For the remaining sales, which are sent from the Companyโs distribution centers directly to hospitals and medical facilities, as well asโฆView โ
Did Revenues Turn Into Profits?
No. It lost $113.4M in FY2024.
10-K for FY2024, filed Mar 5, 2025
โ$126.2MView โ
10-K for FY2024, filed Mar 5, 2025
โ$113.4MView โ
10-K for FY2024, filed Mar 5, 2025
โ$29.2MView โ
How Were They Changing?
-
Apr 3, 2025
Globus Medical completed its merger with Nevro
Nevro became a wholly owned subsidiary of Globus.
Sources
8-K, filed Apr 3, 2025
On April 3, 2025, the Merger was completed. Upon the consummation of the Merger, Nevro became a wholly owned subsidiary of Globus.View โ
Grew. Revenue grew 13% in 4 years, from $362M in FY2020 to $408.5M in FY2024, about 3% a year.
Added SI-joint fusion devices
The older report describes the Senza spinal cord stimulation system; the latest report also includes minimally invasive SI-joint treatments through fusion devices acquired with Vyrsa.
10-K for FY2021, filed Feb 23, 2022 10-K for FY2024, filed Mar 4, 2025OverviewView โ
Who Did They Compete With?
Competes with Medtronic, Boston Scientific, Abbott Laboratories, Saluda, Biotronik, PainTeq, and SI Bone
10-K for FY2024, filed Mar 4, 2025We compete in the SCS market for chronic pain. We also compete with spine surgeries, in particular re-operations. Currently, our majorโฆView โ
Loading...
